­
­
­
­

Inventi Impact: Oncology

Articles

  • Inventi:hoc/22794/17
    Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients\nwith Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study
    01-Jan-1970 Research 2017 : July - September
    Sung Han Kim, Sohee Kim, Byung-Ho Nam, Sang Eun Lee, Choung-Soo Kim, Ill Young Seo, Tae Nam Kim, Sung-Hoo Hong, Tae Gyun Kwon, Seong Il Seo, Kwan Joong Joo, Kanghyon Song, Cheol Kwak, Jinsoo Chung

    We aimed to identify prognostic factors associated with progression-free survival (PFS) and overall survival (OS) in metastatic\nrenal cell carcinoma (mRCC) patients treated with sorafenib. We investigated 177 patients, including 116 who received sorafenib\nas first-line therapy, using the Cox regression model. During a median follow-up period of 19.2 months, the PFS and OS were 6.4\nand 32.6 months among all patients and 7.4 months and undetermined for first-line sorafenib-treated patients, respectively. Clinical\nT3-4 stage (hazard ratio [HR] 2.56) and a primary tumor size >7 cm(HR 0.34) were significant prognostic factors for PFS among all\npatients, as were tumor size >7 cm(HR 0.12), collecting system invasion (HR 5.67), and tumor necrosis (HR 4.11) for OS (

    How to Cite this Article
    CC Compliant Citation: Sung Han Kim, Sohee Kim, Byung-Ho Nam, et al., â??Primary Tumor Characteristics Are Important Prognostic\nFactors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study,â? BioMed Research\nInternational, vol. 2017, Article ID 9215930, 13 pages, 2017. doi:10.1155/2017/9215930, http://creativecommons.org/licenses/\nby/4.0/.
    Download Full Text